《股市簡訊》中國邁威生物A/H股齊漲，血液瘤藥物臨床試驗獲批

路透中文

06/24

《股市簡訊》中國邁威<a href="https://laohu8.com/S/000504">生物</a>A/H股齊漲，血液瘤藥物臨床試驗獲批

* 中國生物科技公司--邁威生物H股2493.HK周三早盤一度上揚2.4%，其A股688062.SS亦漲4.7%。

* 該公司此前公告稱，國家藥品監督管理局批准注射用6MW5311用於血液瘤（急性髓系白血病、慢性粒單核細胞白血病以及多發性骨髓瘤）適應症的臨床試驗申請。

* 邁威生物A股今年迄今跌27.5%，同期滬深300指數.CSI300上揚6%。

* 中證醫藥100指數.CSI000978盤中一度升2.3%。（完）

更多股市簡訊請點選CN-CMN-HOT

(發稿徐凱文；審校張喜良)

((kaiwen.xu@thomsonreuters.com))

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2645505866"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645505866\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645505866?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-06-24 10:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645505866","market":"us","top_or_hot":-1,"title":"《股市簡訊》中國邁威生物A/H股齊漲，血液瘤藥物臨床試驗獲批","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市簡訊》中國邁威<a href=\"https://laohu8.com/S/000504\">生物</a>A/H股齊漲，血液瘤藥物臨床試驗獲批</title></head><body><p>* 中國生物科技公司--邁威生物H股<span>2493.HK</span>周三早盤一度上揚2.4%，其A股<span>688062.SS</span>亦漲4.7%。</p><p>* 該公司此前公告稱，國家藥品監督管理局批准注射用6MW5311用於血液瘤（急性髓系白血病、慢性粒單核細胞白血病以及多發性骨髓瘤）適應症的臨床試驗申請。</p><p>* 邁威生物A股今年迄今跌27.5%，同期滬深300指數<span>.CSI300</span>上揚6%。</p><p>* 中證醫藥100指數<span>.CSI000978</span>盤中一度升2.3%。（完）</p><p>更多股市簡訊請點選<span>CN-CMN-HOT</span></p><p> (發稿 徐凱文；審校 張喜良)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市簡訊》中國邁威生物A/H股齊漲，血液瘤藥物臨床試驗獲批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市簡訊》中國邁威生物A/H股齊漲，血液瘤藥物臨床試驗獲批\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2026-06-24 10:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市簡訊》中國邁威<a href=\"https://laohu8.com/S/000504\">生物</a>A/H股齊漲，血液瘤藥物臨床試驗獲批</title></head><body><p>* 中國生物科技公司--邁威生物H股<span>2493.HK</span>周三早盤一度上揚2.4%，其A股<span>688062.SS</span>亦漲4.7%。</p><p>* 該公司此前公告稱，國家藥品監督管理局批准注射用6MW5311用於血液瘤（急性髓系白血病、慢性粒單核細胞白血病以及多發性骨髓瘤）適應症的臨床試驗申請。</p><p>* 邁威生物A股今年迄今跌27.5%，同期滬深300指數<span>.CSI300</span>上揚6%。</p><p>* 中證醫藥100指數<span>.CSI000978</span>盤中一度升2.3%。（完）</p><p>更多股市簡訊請點選<span>CN-CMN-HOT</span></p><p> (發稿 徐凱文；審校 張喜良)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02493","symbol_name":"邁威生物-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nL4S42W08K:1","article_id":"2645505866","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645505866","pubTimestamp":1782269829,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市簡訊》中國邁威生物A/H股齊漲，血液瘤藥物臨床試驗獲批* 中國生物科技公司--邁威生物H股2493.HK周三早盤一度上揚2.4%，其A股688062.SS亦漲4.7%。* 該公司此前公告稱，國家藥品監督管理局批准注射用6MW5311用於血液瘤適應症的臨床試驗申請。* 邁威生物A股今年迄今跌27.5%，同期滬深300指數.CSI300上揚6%。* 中證醫藥100指數.CSI000978盤中一度升2.3%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688062":"迈威生物-U","02493":"迈威生物-B","BK1161":"生物科技","BK0239":"医药制造"},"translate_title":"\"Stock Market Newsletter\" China's Maiwei Biotech A/H shares rose, and clinical trials of hematoma drugs were approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688062":0.9,"02493":0.9},"content_text":"《股市簡訊》中國邁威<a href=\"https://laohu8.com/S/000504\">生物</a>A/H股齊漲，血液瘤藥物臨床試驗獲批* 中國生物科技公司--邁威生物H股2493.HK周三早盤一度上揚2.4%，其A股688062.SS亦漲4.7%。* 該公司此前公告稱，國家藥品監督管理局批准注射用6MW5311用於血液瘤（急性髓系白血病、慢性粒單核細胞白血病以及多發性骨髓瘤）適應症的臨床試驗申請。* 邁威生物A股今年迄今跌27.5%，同期滬深300指數.CSI300上揚6%。* 中證醫藥100指數.CSI000978盤中一度升2.3%。（完）更多股市簡訊請點選CN-CMN-HOT (發稿 徐凱文；審校 張喜良) ((kaiwen.xu@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}